Two preclinical programs reported novel inhibitors against cancer targets. Insilico Medicine disclosed KIF18A inhibitors with reported antitumor activity from synthesis and profiling studies. Separately, Zymedi announced patented lysyl‑tRNA synthetase (KARS) inhibitors aimed at blocking cancer metastasis. Both disclosures focus on early‑stage small molecules targeting mechanisms implicated in tumor growth and spread. These research and IP moves reflect ongoing diversification of oncology target space beyond canonical kinases, with companies protecting chemistry and seeking translational paths. For biotech partnering and licensing teams, these assets may become candidates for optimization or integration into combination strategies if preclinical models validate tolerability and efficacy.